Dr. Yaqubi is Board-Certified in Psychiatry with a strong specialty in helping patients struggling with Depression, Bipolar Disorder, and Anxiety Disorders. He completed a fellowship in Psychosomatic Medicine and is also experienced in treating neuropsychiatric disorders, e.g., Dementia or Parkinson’s disease associated with mood or anxiety. He is also trained in psychodynamic psychotherapy and Cognitive Behavioral Therapy.
Dr. Yaqubi takes a holistic approach to patient care and treatment plans, considering biological, psychological, and social factors. He has found that being in tune with his patient’s emotional pain is the key to developing a good rapport. To empathize with his patient’s emotional pain and be able to reduce their suffering is his focus at all times.
Through his years of treating patients with depression and other mood disorders, medication and therapy are basic tools that he has used successfully to find relief from suffering. But not all the patients fully respond to these therapeutic tools. For Dr. Yaqubi, Transcranial Magnetic Stimulation (TMS) is another non-invasive therapeutic tool that can play a crucial role for those with treatment-resistant mood or anxiety disorders.
He joins Mindful Health Solutions in early 2021.
Being a nature lover, he enjoys spending his free time hiking, camping, biking, running. When not outdoors embracing the beauty of Northern California, he also spends his time traveling, reading, or pursuing his interest in ballroom dance.
Dr. Yaqubi received his medical degree from the Shahid Beheshti University of Medical Sciences (SBMU) in Tehran, Iran. To further his academic career, he moved to the US and completed a Postdoctoral Research Fellowship in the Department of Genetics & Genomics at Boston University School of Medicine. He conducted research with a focus on the epigenetic dysregulation in patients with bipolar disorder and schizophrenia. He also conducted clinical research on the efficacy of COMT inhibitor (COMTAN®) on patients with schizophrenia and bipolar disorder with or without substance use.
He continued his research work as a Clinical Research Assistant at Stanford University School of Medicine. He worked on an NIH-funded study (GenePAD) on the genetics of peripheral arterial disease, evaluating the long-term quality of life and depression in geriatric patients with vascular disease.
He completed his Psychiatry Residency followed by a Fellowship in Psychosomatic Medicine/ Consultation-Liaison at Icahn School of Medicine at Mount Sinai in New York City. During his residency, he began to develop and nurture his teaching interest and talent. As Chief Resident, he taught and mentored other budding psychiatrists and found a passion for teaching, which has continued throughout his career. His fellowship was focused on Transplant Psychiatry, Psycho-oncology, and Neuropsychiatry. Dr. Yaqubi continued working as a Transplant Psychiatrist at Ricanati/Miller Transplant Institute in Mount Sinai Hospital, where he served as an Assistant Professor of Psychiatry, teaching and supervising medical students, residents, and fellows.
Most recently, he was Assistant Clinical Professor of Psychiatry at the Icahn School of Medicine, providing psychiatric care to patients at Beth Israel Hospital and leading a multidisciplinary team including residents, nursing, and social workers in the Comprehensive Psychiatric Emergency Program.
James W. Murrough, Sahab Yaqubi, Sehrish Sayed, Dennis S. Charney. “Emerging Drugs for the Treatment of Anxiety”. Expert Opin Emerg Drugs 2015 May 26:1-14. Cited in PubMed; PMID: 26012843
Hamid M Abdolmaleky, Sahab Yaqubi, Panos Papageorgis, Arthur W. Lambert, Sait Ozturk, Vadivelu Sivaraman and Sam Thiagalingam. “Epigenetic dysregulation of HTR2A in the Brain of patients with schizophrenia and bipolar disorder”. Schizophrenia Research 129 (2011) pp. 183-190. Cited in PubMed; PMID: 21550210
Rahim Shafa, Hamid Abdolmaleky, Sahab Yaqubi, Casandra L Smith, Nassir Ghaemi. Entacapone as an Anti-Craving Treatment in Substance Abuse and Dependence. The American Journal on Addictions 17(4), pp. 331-332, 2008
Brian Medina, Sahab Yaqubi, Kara Martin, Bill Lin and Ahmad Salehi.” Increased Gaba-ergic terminals in Ts65Ds mice could be linked to a fragment of MMU16 between MRPL39 to TIAM1 genes.” Poster, Presented in Stanford Institute for Neuro-Innovation and Translational Neurosciences Annual Neuroscience Research Conference Oct2011, Watsonville, CA.